Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) has announced a non-brokered private placement expected to raise gross proceeds of approximately C$5 million, which will be used to advance its ONC010 program through manufacturing and preclinical testing activities. The financing also supports development of the company’s SynoGraph(TM) platform and provides working capital for general corporate purposes.
Under the terms, the company will issue 6,764,069 units at a price of C$0.7392 per unit. Each unit consists of one common share and one warrant, with each warrant exercisable at C$0.90 per share for a period of three years. The offering is being conducted under Canada’s Listed Issuer Financing Exemption, meaning the securities issued will not be subject to a hold period under applicable Canadian securities laws. The financing is expected to close on or about July 10, 2026, subject to regulatory approvals, including approval from Cboe Canada.
This capital raise is a critical step for Onco-Innovations as it seeks to bring its patented technology targeting solid tumours closer to clinical application. The company, which is dedicated to cancer research and treatment, has secured an exclusive worldwide license to patented technology that focuses on solid tumours, a major area of unmet medical need. Solid tumours account for the majority of cancer cases globally, and innovative therapies are urgently needed to improve patient outcomes.
The proceeds will directly support the ONC010 program, which is at the forefront of the company’s pipeline. Manufacturing and preclinical testing are essential milestones before human trials can begin, and this funding ensures that Onco-Innovations can proceed without delay. Additionally, the SynoGraph platform, which is being developed alongside ONC010, could provide a versatile tool for future cancer therapies.
For investors, this announcement signals that Onco-Innovations is executing on its development strategy. The private placement structure, with a warrant exercise price above the unit price, suggests confidence in the company’s valuation and future prospects. The absence of a hold period on the securities may also provide liquidity for investors sooner than typical offerings.
The broader implications for the oncology sector are significant. If ONC010 proves successful in preclinical studies, it could pave the way for a new class of treatments for solid tumours. The cancer research community is closely watching developments in this area, and Onco-Innovations’ ability to secure funding in a challenging capital market underscores the potential of its technology.
To view the full press release, visit https://www.nnw.fm/QatCe. For the latest news and updates on Onco-Innovations, visit the company’s newsroom at https://nnw.fm/ONNVF.
